Complementary and Alternative Medicine and Multiple Sclerosis

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 465-480

  Bowling, Allen C ^a,b  

^a Colorado Neurological Institute ^*  (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Complementary and alternative medicine; Demyelinating disease; Multiple sclerosis; Unconventional medicine

Indexed keywords

ANTIOXIDANT; BEE VENOM; CANNABIS; CYANOCOBALAMIN; DENTAL ALLOY; NALTREXONE; VITAMIN D;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANAPHYLAXIS; CHINESE HERB; CHINESE MEDICINE; CRANBERRY; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; ECHINACEA; GINKGO BILOBA; HUMAN; HYPERBARIC OXYGEN; HYPERICUM PERFORATUM; IMAGERY; MASSAGE; MULTIPLE SCLEROSIS; NAUSEA; NOMENCLATURE; PRIORITY JOURNAL; PRURITUS; RASH; REFLEXOLOGY; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TAI CHI; VOMITING; YOGA;

COMPLEMENTARY THERAPIES; HUMANS; MULTIPLE SCLEROSIS;

EID: 79952833108     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.12.006     Document Type: Review

References (72)

1. Bowling A.C. Complementary and alternative medicine and multiple sclerosis 2007, Demos Medical Publishing, New York.
2. Bowling A.C., Stewart T.M. Current complementary and alternative therapies of multiple sclerosis. Curr Treat Options Neurol 2003, 5:55-68.
3. Bowling A.C., Stewart T.M. Dietary supplements and multiple sclerosis: a health professional's guide 2004, Demos Medical Publishing, New York.
4. Polman C.H., Thompson A.J., Murray T.J., et al. Multiple sclerosis: the guide to treatment and management 2006, Demos Medical Publishing, New York, p. 117-79.
5. Bowling A.C. Unconventional medicine and multiple sclerosis: the role of conventional health providers. Multiple sclerosis 3 (blue books of neurology series) 2010, 355-370. Saunders, Philadelphia. C.F. Lucchinetti, R. Hohlfeld (Eds.).
6. Eisenberg D., Davis R., Ettner S., et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998, 280:1569-1575.
7. Shinto L., Yadav V., Morris C., et al. Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis. Mult Scler 2006, 12:94-100.
8. Soe S.T.E., Kopsky D.J., Jongen P.J., et al. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler 2009, 15:1376-1377.
9. Donnelan C.P., Shanley J. Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary, single-blind randomized controlled trial. Clin Rehabil 2008, 22:195-205.
10. NIH consensus development panel on acupuncture. JAMA 1998, 280:1518-1524.
11. Wesselius T., Heersema D.J., Mostert J.P., et al. A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 2005, 65:1764-1768.
12. Castro H.J., Mendez-Inocencio J.I., Omidvar B., et al. A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. Allergy Asthma Proc 2005, 26:470-476.
13. Song H.-S., Wray S.H. Bee sting optic neuritis. J Clin Neuroophthalmol 1991, 11:1145-1149.
14. NASA/MS Cooling Study Group A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003, 60:1955-1960.
15. Casetta I., Invernizzi M., Granieri E. Multiple sclerosis and dental amalgam: case control study in Ferrara, Italy. Neuroepidemiology 2001, 20:134-137.
16. NIH Conference Assessment Effects and side-effects of dental restorative materials. Adv Dent Res 1992, 6:1-144.
17. Ekstrand J., Bjorkman L., Edlund C., et al. Toxicological aspects on the release and systemic uptake of mercury from dental amalgam. Eur J Oral Sci 1998, 106:678-686.
18. Eley B.M., Cox S.W. The release, absorption, and possible health effects of mercury from dental amalgam: a review of recent findings. Br Dent J 1993, 175:355-362.
19. Van Meeteren M.E., Teunissen C.E., Dijkstra A., et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 2005, 59:1347-1361.
20. Marracci G.H., Jones R.E., McKeon G.P., et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002, 131:104-114.
21. Scott G.S., Spitsin S.V., Kean R.B., et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002, 99:16303-16308.
22. Yadav V., Marracci G., Lovera J., et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005, 11:159-165.
23. Mai J., Sorenson P., Hansen J. High dose antioxidant supplementation to MS patients: effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol Trace Elem Res 1990, 24:109-117.
24. Markowitz C.E., Spitsin S., Zimmerman V., et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009, 15:619-625.
25. Gonsette R.E., Sindic C., D'hooge M.B., et al. Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon-beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 2010, 16:455-462.
26. Guay D.R. Cranberry and urinary tract infections. Drugs 2009, 69:775-807.
27. Jellin J.M., Gregory P.J., Batz F., et al. Pharmacist's letter/prescriber's letter natural medicines comprehensive database 2010, Therapeutic Research Faculty, Stockton (CA). 8th edition.
28. Bowling A.C., Ibrahim R., Stewart T.M. Alternative medicine and multiple sclerosis: an objective review from an American perspective. Int J MS Care 2000, 2:14-21.
29. Brochet B., Guinot P., Orgogozo J., et al. Double-blind, placebo controlled, multicentre study of ginkgolide B in treatment of acute exacerbations for multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 58:360-362.
30. Lovera J., Bagert B., Smoot K., et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007, 13:376-385.
31. Johnson S.K., Diamond B.J., Rausch S., et al. The effect of Ginkgo biloba on functional measure in multiple sclerosis: a pilot randomized controlled trial. Explore (NY) 2006, 2:19-24.
32. Werneke U., Horn O., Taylor D.M. How effective is St. John's wort? The evidence revisited. J Clin Psychiatry 2004, 65:611-617.
33. Kira J., Tobimatus S., Goto I. Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Intern Med 1994, 33:82-86.
34. Loder C., Allawi J., Horrobin D.F. Treatment of multiple sclerosis with lofepramine, L-phenylalanine, and vitamin B-12: mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Med Hypotheses 2002, 59:594-602.
35. Wade D.T., Young C.A., Chaudhuri K.R., et al. A randomized placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the " Cari Loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 73:246-249.
36. Goodkin D., Jacobsen D., Galvez N., et al. Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol 1994, 51:1110-1114.
37. Weinstock-Guttman B., Gallagher E., et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004, 10:170-175.
38. Smolders J., Damoiseaux J., Menheere P. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008, 194:7-17.
39. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol 2010, 9:599-612.
40. Mowry E.M., Krupp L.B., Milazzo M., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67:618-624.
41. Simpson S., Taylor B., Blizzard L., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010, 68:193-203.
42. Burton J.M., Kimball S., Vieth R., et al. A Phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859.
43. Wingerchuk D.M., Lesaux J., Rice G.P., et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:1294-1296.
44. Dietary reference intakes for calcium and vitamin D 2010, The National Academies Press, Washington, DC. A.C. Ross, C.L. Taylor, A.L. Yaktine (Eds.).
45. Stewart T.M., Bowling A.C. Polyunsaturated fatty acid supplementation in MS. Int MS J 2005, 12:88-93.
46. Mehta L.R., Dworkin R.H., Schwid S.R. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 2009, 5:82-92.
47. Swank R., Dugan B. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990, 336:37-39.
48. Bates D., Cartlidge N., French J., et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989, 52:18-22.
49. Weinstock-Guttman B., Baier M., Park Y., et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005, 73:392-404.
50. Myhr K.-M., Reinertsen S., Beiske A.G., et al. Omega-3 fatty acids treatment in relapsing-remitting multiple sclerosis. Neurology 2010, 74(Suppl2):A370.
51. Maguire B.L. The effects of imagery on attitudes and moods in multiple sclerosis patients. Altern Ther Health Med 1996, 2:75-79.
52. Fischer B.H., Marks M., Reich T. Hyperbaric oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. N Engl J Med 1983, 308:181-186.
53. Bennett M., Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004, 1. CD003057.
54. Kleijnen J., Knipschild P. Hyberbaric oxygen for multiple sclerosis: review of controlled trials. Acta Neurol Scand 1995, 91:330-334.
55. Bennett M., Heard R. Hyperbaric oxygen therapy for multiple sclerosis. CNS Neurosci Ther 2010, 16:115-124.
56. Gironi M., Martinelli-Boneschi F., Sacerdote P., et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008, 14:1076-1083.
57. Zagon I.S., Rahn K.A., Turel A.P., et al. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) 2009, 234:1383-1392.
58. Sharafaddinzadeh N., Moghtaderi A., Kashipazha D., et al. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010, 16(8):964-969.
59. Cree B.A., Kornyeyeva E., Goodin D.S. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010, 68:145-150.
60. Bowling A.C. Cannabinoids in MS-are we any closer to knowing how best to use them?. Mult Scler 2006, 12:523-525.
61. Zajicek J., Sanders H.P., Wright D.E., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005, 76:1664-1669.
62. Barnes M.P. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006, 7:607-615.
63. Centonze D., Mori F., Koch G., et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009, 30:531-534.
64. Hernandez-Reif M., Field T., Field T., et al. Multiple sclerosis patients benefit from massage therapy. J Bodyw Mov Ther 1998, 2:168-174.
65. Ernst E. Is reflexology an effective intervention? A systematic review of randomized controlled trials. Med J Aust 2009, 191:263-266.
66. Siev-Nur I., Gamus D., Lerner-Geva L., et al. Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 2003, 9:356-361.
67. Hughes C.M., Smyth S., Lowe-Strong A.S. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomized sham-controlled clinical trial. Mult Scler 2009, 15:1329-1338.
68. Mackereth P.A., Booth K., Hillier V.F., et al. What do people talk about during reflexology? Analysis of worries and concerns expressed during sessions for patients with multiple sclerosis. Complement Ther Clin Pract 2009, 15:85-90.
69. Husted C., Pham L., Hekking A. Improving quality of life for people with chronic conditions: the example of t'ai chi and multiple sclerosis. Altern Ther Health Med 1999, 5:70-74.
70. Mills M., Allen J. Mindfulness of movement as a coping strategy in multiple sclerosis. A pilot study. Gen Hosp Psychiatry 2000, 22:425-431.
71. Oken B.S., Kishiyama S., Zajdel D., et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004, 62:2058-2064.
72. Velikonja O., Curic K., Ozura A., et al. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 2010, 112(7):597-601.